The Trump administration’s push to bring US drug spending down is a powerful incentive for pharmaceutical companies to boost prices and reduce access elsewhere in the world, a study found.
Mostramos la idea principal publicamente. Crea una cuenta gratis para seguir leyendo el articulo completo, guardarlo, comentarlo y conectarlo con contexto de mercados y OSINT.